#United States #San Francisco #Hagens Berman #Embecta Corp. #NASDAQ EMBC

Investigation into Embecta Corp.

Hagens Berman, a prominent national law firm focused on protecting shareholders' rights, has initiated an investigation into Embecta Corp. (NASDAQ: EMBC). This inquiry follows a class action lawsuit lodged against the company in the U.S. District Court for the District of New Jersey. The lawsuit claims that Embecta misrepresented the stability of its insulin pen needle business, potentially violating federal securities laws.

Background of the Case

The core allegation in the class action includes claims that Embecta's management misled investors about the commercial strength and stability of their flagship insulin pen needle line. According to the lawsuit, during the designated class period—from November 25, 2025, to May 4, 2026—Embecta executives assured investors of the resilience of their pen needle portfolio, using terms such as "stable" and "incredibly resolute."

However, as the lawsuit alleges, these statements were far from accurate. Evidence suggests that Embecta was actually experiencing a significant downturn, characterized by a substantial loss of market share, particularly from a major customer, and a general decline in market volume within the retail sector. The management's alleged knowledge—or willful ignorance—of these issues raises serious questions about the validity of their optimistic statements to investors, ultimately leading to substantial financial losses.

Revelations and Market Reaction

The turning point in this scenario occurred on May 5, 2026, when Embecta released its second-quarter financial results for fiscal year 2026. During this announcement, the company conceded to a dramatic revenue decline and cited numerous challenges plaguing the U.S. pen needle market, directly contradicting its prior claims of stability. In light of these revelations, Embecta drastically lowered its earnings guidance for the year by an alarming 43% and slashed its quarterly dividend from 15 cents to just one cent per share, representing a staggering 93% reduction.

The immediate market reaction was severe, with Embecta's stock price plummeting by a staggering 57.8% within a single trading day, reflecting the investors' shock at the stark contrast between prior assurances and the disclosed financial realities.

Reed Kathrein, the leading partner from Hagens Berman overseeing this investigation, stated, "Our investigation aims to uncover whether Embecta's prior positive comments misled investors, especially in light of the drastic revenue adjustments announced."

Investor Actions

Investors who acquired Embecta shares during the specified class period and suffered financial losses are encouraged to engage with the firm's legal team. Hagens Berman actively seeks to assist these individuals in reporting their losses and may provide a route for potential recovery.

Whistleblower Information

The firm also invites individuals with non-public information concerning Embecta to consider their role in the ongoing investigation. Those providing original information could be eligible for rewards, potentially up to 30% of any successful SEC recovery, via the SEC Whistleblower program. For further details, interested parties can contact Hagens Berman directly.

About Hagens Berman

Hagens Berman is known for its dedication to holding corporations accountable. Specializing in complex litigation, the firm has a notable history of advocating for the rights of investors, whistleblowers, and consumers, securing over $2.9 billion in settlements in response to corporate malpractice. For more updates and legal resources, follow the firm at @ClassActionLaw or visit their website at hbsslaw.com.

This ongoing investigation into Embecta serves as a reminder of the critical importance of corporate transparency and accountability in safeguarding investor interests in today's volatile market landscape.